Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 -2.93%84 Net Margin % is 5.29% as of Mar. 2026, which is 42% below its 10-year median of 9.05. GuruFocus rates SHSE:688315 with a GF Score™ of 84/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Novogene Co ranks better than 78.34% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Novogene Co's Net Income for the
three
months ended in Mar. 2026 was ¥29 Mil. Novogene Co's Revenue for the
three
months ended in Mar. 2026 was ¥556 Mil. Therefore, Novogene Co's net margin for the quarter that ended in Mar. 2026 was 5.29%.
The historical rank and industry rank for Novogene Co's Net Margin % or its related term are showing as below:
SHSE:688315'
s Net Margin % Range Over the Past 10 Years
Min: 2.45 Med: 9.05 Max: 12.07
Current: 7.18
SHSE:688315's Net Margin % is ranked better than 78.34% of 942
companies
in the Biotechnology industry
Industry Median: -89.445
vs SHSE:688315: 7.18
Novogene Co (SHSE:688315) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Novogene Co Net Margin % Related Terms
Novogene Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Novogene Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688315 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Novogene Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Novogene Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novogene Co (SHSE:688315) has a Net Margin % of 5.29% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Novogene Co and its competitors. This is 42% below median its historical median of 9.05. Over the past decade, Novogene Co's Net Margin % has ranged from 2.45 to 12.07. According to the industry distribution chart, Novogene Co ranks #204 out of 942 companies in the Biotechnology industry, placing it in the top 21.7%.
Is Novogene Co's Net Margin % too high?
Novogene Co's current Net Margin % of 5.29% is 42% below median its 10-year median of 9.05. Over the past 10 years, this metric has ranged from a low of 2.45 to a high of 12.07. Based on the distribution chart, Novogene Co ranks #204 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Novogene Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #204 out of 942 companies for Net Margin %. This places Novogene Co in the top 22% of its industry — outperforming the majority of peers. Historically, Novogene Co's own Net Margin % has ranged from 2.45 to 12.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Novogene Co and its competitors. Novogene Co's current Net Margin % is 5.29%, which is 42% below median its own 10-year median of 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥11.94 — trading 25.3% below its estimated fair value. The current Net Margin % is 5.29%, which is 42% below median its 10-year median of 9.05. Novogene Co's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current Net Margin % is 5.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued.
The current stock price of ¥11.94 is trading 25.3% below its estimated GF Value™ of ¥15.99.
GuruFocus considers Novogene Co to be Modestly Undervalued.
Key valuation signals for SHSE:688315:
Net Margin %: 5.29% (42% below median its 10-year median of 9.05)
GF Value™: ¥15.99 vs. price of ¥11.94 (25.3% below fair value)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
84GF Score
Get the complete analysis for SHSE:688315
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
